您的位置: 首页 > 农业专利 > 详情页

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
专利权人:
Nicholas J Donato
发明人:
Nicholas J Donato,Doriano Fabbro,Paul W Manley,Jurgen Mestan,Markus Warmuth,Michael Hallek,Moshe Talpaz,Ji Wu
申请号:
US11285664
公开号:
US08268837B2
申请日:
2005.11.22
申请国别(地区):
US
年份:
2012
代理人:
摘要:
The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof to pharmaceutical compositions comprising said combinations and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充